MiMedx Group Inc
$ 6.90
-2.54%
26 Dec - close price
- Market Cap 1,021,905,000 USD
- Current Price $ 6.90
- High / Low $ 7.13 / 6.74
- Stock P/E 25.56
- Book Value 1.61
- EPS 0.27
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.19 %
- 52 Week High 9.71
- 52 Week Low 5.79
About
MiMedx Group, Inc. (MDXG) is a prominent regenerative medicine company based in Marietta, Georgia, that focuses on the development and commercialization of advanced placental tissue allografts for wound care and surgical applications. These pioneering products are designed to enhance healing processes and improve patient outcomes, leveraging proprietary technologies to meet the evolving demands of healthcare providers. With a robust research foundation and a commitment to innovation, MiMedx is well-positioned to lead advancements in the regenerative medicine field and address critical healthcare challenges.
Analyst Target Price
$12.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-29 | 2025-04-28 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-04-30 | 2024-02-28 | 2023-10-30 | 2023-08-01 | 2023-05-02 | 2023-02-28 |
| Reported EPS | 0.15 | 0.1 | 0.05 | 0.07 | 0.05 | 0.12 | 0.07 | 0.32 | 0.06 | -0.0046 | -0.06 | -0.02 |
| Estimated EPS | 0.058 | 0.054 | 0.055 | 0.075 | 0.04 | 0.08 | 0.05 | 0.07 | 0.05 | -0.02 | -0.09 | -0.04 |
| Surprise | 0.092 | 0.046 | -0.005 | -0.005 | 0.01 | 0.04 | 0.02 | 0.25 | 0.01 | 0.0154 | 0.03 | 0.02 |
| Surprise Percentage | 158.6207% | 85.1852% | -9.0909% | -6.6667% | 25% | 50% | 40% | 357.1429% | 20% | 77% | 33.3333% | 50% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXG
2025-12-27 07:09:33
Harbor Capital Advisors Inc. significantly reduced its stake in MiMedx Group, Inc., selling 71.3% of its shares in Q3 and now owning approximately 0.23% of the company. Additionally, insider Kimberly Maersk-Moller also sold a substantial portion of her holdings. Despite these sales, MiMedx Group trades near $7 with a "Moderate Buy" consensus rating from analysts and a $11 average target price.
2025-12-23 09:09:20
MiMedx Group, Inc. has announced an exclusive U.S. distribution agreement with Regen Lab USA LLC for their RegenKit®-Wound Gel. This fully autologous platelet-rich plasma and thrombin serum wound gel broadens MIMEDX's Advanced Wound Care portfolio. The kits, FDA-approved in 2022, are nationally covered for diabetic chronic wounds.
2025-12-23 08:08:56
MIMEDX Group, Inc. has announced an exclusive U.S. distribution agreement with Regen Lab USA LLC for their RegenKit®-Wound Gel, an autologous platelet-rich plasma and thrombin serum wound gel. This agreement broadens MIMEDX's Advanced Wound Care portfolio with a differentiated autologous solution for chronic wounds, which is FDA approved and covered by CMS. The company expects this addition to strengthen its competitive position as new Local Coverage Determination guidelines are implemented in 2026.
2025-12-23 07:09:33
MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its first-quarter 2025 operating and financial results after market close on Wednesday, April 30, 2025. The company will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can access the call via webcast or phone.
2025-12-22 16:51:00
MiMedx Group, Inc. has announced an exclusive agreement with Regen Lab USA LLC to distribute RegenKit®-Wound Gel in the United States, expanding its Advanced Wound Care portfolio. This FDA-approved wound gel, covered by Medicare, utilizes autologous platelet-rich plasma to treat chronic wounds. The partnership positions MiMedx strongly ahead of upcoming changes in Local Coverage Determination implementation in 2026.
2025-12-22 15:09:47
MIMEDX Group, Inc. has announced an exclusive U.S. distribution agreement with Regen Lab USA LLC for their RegenKit®-Wound Gel. This fully autologous platelet-rich plasma and thrombin serum wound gel adds a differentiated option to MIMEDX's Advanced Wound Care portfolio and is covered nationally by CMS and LCD for diabetic chronic wounds. The agreement strengthens MIMEDX's competitive position as it expands its wound treatment offerings.
